FIELD: biotechnology.
SUBSTANCE: invention relates to the field of biotechnology, in particular to the use of an Fc-fusion protein for treating cancer, wherein said Fc-fusion protein is a homodimer of two polypeptides, each of which contains (i) an IgG immunoglobulin Fc domain and (ii) a heterologous polypeptide comprising the human IL-10 sequence from SEQ ID NO: 1 or a variant thereof, wherein the heterologous polypeptide is covalently bonded to the N-terminus of the Fc domain via a polypeptide linker, and two heterologous polypeptides are non-covalently bonded into a homodimer. Also disclosed is a pharmaceutical composition for treating cancer. Invention also relates to a method for preventing or treating cancer, a method for stimulating immunity in a subject and a method for restoring the ability to respond to immunotherapy in a subject.
EFFECT: invention provides the use of the IL-10 / Fc fusion protein as an immunotherapy enhancer.
31 cl, 7 dwg, 1 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSION PROTEIN COMPRISING IL-2 PROTEIN AND CD80 PROTEIN AND ITS USE | 2019 |
|
RU2811541C2 |
| COMPOSITION FOR CULTURING NATURAL KILLER CELLS AND METHOD OF PRODUCING NATURAL KILLER CELLS USING SAME | 2020 |
|
RU2824216C1 |
| COMPOSITIONS AND METHODS FOR CONNECTING EXTRACELLULAR DOMAINS OF TYPE I AND TYPE II AS HETEROLOGOUS CHIMERIC PROTEINS | 2016 |
|
RU2766200C1 |
| IMMUNOCYTOKINES AND THEIR USE | 2021 |
|
RU2818371C1 |
| FUSED PROTEINS WITH ALBUMIN-BINDING DOMAINS | 2018 |
|
RU2786444C2 |
| NOVEL FUSION PROTEIN SPECIFIC FOR CD137 AND PD-L1 | 2019 |
|
RU2818349C2 |
| BIFUNCTIONAL PROTEINS COMBINING CHECKPOINT BLOCKADE FOR TARGETED THERAPY | 2019 |
|
RU2756899C1 |
| COMPOSITION FOR CULTURING REGULATORY T-CELLS AND ITS APPLICATION | 2020 |
|
RU2807802C1 |
| IL-12 HETERODIMERIC FC FUSION PROTEINS | 2019 |
|
RU2819097C2 |
| INTERLEUKIN 15 PROTEIN COMPLEX AND USE THEREOF | 2015 |
|
RU2711979C2 |
